Drug intelligence / Profile preview

Oncoxin + Viusid

Development stage
Unknown
Lead developer
Laboratorios Catalysis
Administration
Oral
01

Overview

Oncoxin + Viusid (Oncoxin-Viusid, OV) is a **nutritional supplement** comprising a mixture of antioxidants, amino acids, vitamins, minerals, and plant extracts, notably including glycine, glucosamine, arginine, cystine, malic acid, monoammonium glycyrrhizinate, ascorbic acid, zinc sulfate, green tea extract (epigallocatechin gallate), and cinnamon extract, among others. It is formulated by Laboratorios Catalysis. OV is designed to provide **antioxidant**, **immunomodulatory**, and reported **anti-tumor supportive effects**. Mechanisms include inhibition of pro-tumor factors (e.g., tissue necrosis factor, cyclooxygenase 2), restoration of apoptosis (p53, BAX, caspase-3 activation, Bcl-2 inhibition), stimulation of interferons and interleukin 12, and increased phagocytic function of macrophages and T-helper cells. Clinically, it is studied as a supportive agent to reduce the toxicity and adverse events associated with chemotherapy and radiotherapy in oncology patients (e.g., cervical, endometrial, prostate cancer) and to improve quality of life and hematological parameters during cancer therapy[1][3].

Brand names
Ocoxin-Viusid
Other names
OV

Beyond the preview

Go deeper on Oncoxin + Viusid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncoxin + Viusid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call